PRKAA2 (AMPKα2) — AMP-Activated Protein Kinase Catalytic Subunit Alpha 2
Pathway Diagram
Mermaid diagram (expand to render)
<div class="infobox infobox-gene">
<h3>PRKAA2 (AMPKalpha2)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>Protein Kinase AMP-Activated Catalytic Subunit Alpha 2</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>PRKAA2 (AMPKalpha2, AMPK)</td></tr> [@curry2018]
<tr><td><strong>Chromosomal Location</strong></td><td>1p32.2</td></tr> [@dasgupta2016]
<tr><td><strong>NCBI Gene ID</strong></td><td>[5563](https://www.ncbi.nlm.nih.gov/gene/5563)</td></tr> [@thornton2022]
<tr><td><strong>OMIM</strong></td><td>[600497](https://omim.org/entry/600497)</td></tr> [@kim2016]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000162409](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162409)</td></tr> [@cai2012]
<tr><td><strong>UniProt (Protein)</strong></td><td>[P54646 (5'-AMP-activated protein kinase catalytic subunit alpha-2)](https://www.uniprot.org/uniprot/P54646)</td></tr> [@poels2020]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Type 2 Diabetes</td></tr>
</table>
</div>
Overview
PRKAA2 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 2) encodes the α2 catalytic subunit of AMP-activated protein kinase (AMPK), the master cellular energy sensor and metabolic regulator. AMPK is a heterotrimeric complex comprising a catalytic α subunit ([PRKAA1/α1](/genes/prkaa1) or PRKAA2/α2), a scaffolding β subunit (PRKAB1/β1 or PRKAB2/β2), and a regulatory γ subunit (PRKAG1/γ1, PRKAG2/γ2, or PRKAG3/γ3). When cellular ATP is depleted and AMP/ADP levels rise, AMPK is activated and phosphorylates hundreds of downstream targets to restore energy homeostasis by stimulating catabolic pathways (glucose uptake, fatty acid oxidation, [autophagy](/mechanisms/autophagy), [mitophagy](/mechanisms/mitophagy)) and suppressing anabolic pathways (protein synthesis via [mTORC1](/genes/mtor) inhibition, lipogenesis, gluconeogenesis).
In the brain, PRKAA2/AMPKα2 is the predominant catalytic isoform in [neurons](/entities/neurons), where it plays essential roles in synaptic plasticity, axonal energy supply, mitochondrial quality control, and neuronal survival under metabolic stress. AMPK dysregulation is a convergent pathomechanism across major neurodegenerative diseases, making PRKAA2 a high-priority therapeutic target.
Gene Structure and Expression
PRKAA2 spans approximately 93 kb on chromosome 1p32.2 and contains 12 exons. The promoter region contains binding sites for [PGC-1α](/genes/ppargc1a), [CREB](/genes/creb1), [MEF2](/genes/mef2c), and FOXO transcription factors. Alternative splicing produces minor transcript variants, but the canonical 552 amino acid isoform predominates.
In the brain, PRKAA2 is the major α-subunit isoform in neurons, with highest expression in the hypothalamus (particularly the arcuate nucleus), [hippocampus](/brain-regions/hippocampus) (CA1, CA3, dentate gyrus), cerebral [cortex](/brain-regions/cortex), and cerebellum. [PRKAA1/α1](/genes/prkaa1) predominates in [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia), while both isoforms are expressed in [oligodendrocytes](/cell-types/oligodendrocytes). The hypothalamic enrichment of PRKAA2 reflects its critical role in whole-body energy sensing and appetite regulation. The [Allen Brain Atlas](https://human.brain-map.org/) confirms neuronal enrichment across cortical layers and hippocampal subfields.
Protein Function and Mechanism
AMPKα2 is a 552 amino acid serine/threonine kinase containing an N-terminal kinase domain, an auto-inhibitory domain (AID), an α-linker region with the β-subunit-interacting domain (β-SID), and a C-terminal domain (CTD) that binds the β and γ subunits.
Activation Mechanisms
AMPK activation requires phosphorylation of Thr172 in the α-subunit activation loop, which is accomplished by three upstream kinases:
[LKB1 (STK11)](/genes/stk11): The constitutively active tumor suppressor kinase that phosphorylates AMPK in response to AMP/ADP binding to the γ subunit. LKB1 is the primary AMPK kinase in most tissues including neurons
CaMKKβ (CAMKK2): Calcium/calmodulin-dependent kinase kinase β activates AMPK independently of AMP/ADP, coupling neuronal Ca²⁺ signaling to energy sensing. This mechanism is particularly important in neurons, where synaptic activity triggers Ca²⁺ influx
TAK1 ([MAP3K7](/genes/map3k7)): Activates AMPK in response to inflammatory cytokines ([TNF-α](/genes/tnf), [IL-1β](/genes/il1b)), linking innate immunity to metabolic adaptationAMP and ADP bind the γ subunit (CBS domains), causing conformational changes that: (i) promote Thr172 phosphorylation by LKB1, (ii) inhibit Thr172 dephosphorylation by protein phosphatases ([PP2A](/entities/pp2a), PP2C), and (iii) allosterically activate the kinase up to 10-fold. ATP competes for the same binding sites, so AMPK is a ratiometric sensor of AMP:ATP and ADP:ATP.
Key Downstream Targets in the Brain
AMPK phosphorylates over 100 substrates. The most neurologically relevant include:
- [mTORC1](/genes/mtor) (via TSC2/Raptor): AMPK phosphorylates [TSC2](/genes/tsc2) (activating the TSC1/TSC2 GAP for Rheb) and [Raptor](/genes/rptor) (directly inhibiting mTORC1). This suppresses protein synthesis and activates [autophagy](/mechanisms/autophagy) — the primary mechanism linking AMPK to proteostasis in neurodegeneration
- [ULK1](/genes/ulk1)/ULK2: AMPK directly phosphorylates ULK1 at S317, S555, and S777 to initiate autophagosome formation, promoting clearance of aggregated proteins and damaged mitochondria
- [TFEB](/genes/tfeb): AMPK activates [TFEB](/entities/tfeb)-mediated lysosomal biogenesis, enhancing the cell's degradative capacity
- [ACC1/2](/genes/acaca): AMPK inhibits acetyl-CoA carboxylase, reducing malonyl-CoA and promoting fatty acid oxidation — critical for axonal energy supply during long-distance transport
- [LATS1](/genes/lats1)/LATS2: AMPK activates Hippo pathway kinases, linking energy stress to YAP/TAZ-dependent transcription
- [BACE1](/genes/bace1): AMPK phosphorylates BACE1, the [β-secretase](/entities/bace1) that cleaves [APP](/genes/app) to generate [amyloid-beta](/proteins/amyloid-beta), modulating amyloidogenic processing
- [Tau](/proteins/tau) ([MAPT](/genes/mapt)): AMPK directly phosphorylates tau at multiple sites (S262, S396, S404), with both protective and pathological consequences depending on the site and cellular context
Energy Sensing at Synapses
PRKAA2/AMPKα2 is particularly important at synapses, where it acts as a local energy gauge:
- Synaptic vesicle recycling and neurotransmitter release are among the most ATP-consuming neuronal processes
- AMPKα2 is enriched at presynaptic terminals and [dendritic spines](/mechanisms/dendritic-spines)
- During intense synaptic activity, local ATP depletion activates AMPK, which reduces neurotransmitter release probability and suppresses mTORC1-dependent local protein synthesis — serving as a homeostatic mechanism that protects synapses from energy failure
- Chronic AMPK activation at synapses, however, impairs [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and synaptic plasticity
Disease Associations
Alzheimer's Disease (AD)
AMPK dysregulation is a prominent feature of [AD](/diseases/alzheimers-disease), with both insufficient and excessive AMPK activity contributing to pathology at different stages:
Beneficial AMPK roles in AD:
- AMPK activation promotes [autophagy](/mechanisms/autophagy) and lysosomal clearance of [amyloid-beta (Aβ)](/proteins/amyloid-beta) aggregates and hyperphosphorylated [tau](/genes/mapt)
- AMPK phosphorylates and inhibits [BACE1](/genes/bace1), reducing amyloidogenic [APP](/entities/app-protein) processing
- AMPK activation by metformin or AICAR improves cognitive function in APP/PS1 mice
- AMPK promotes mitochondrial biogenesis via [PGC-1α](/genes/ppargc1a), restoring mitochondrial function
Detrimental AMPK roles in AD:
- Aberrant AMPK activation directly phosphorylates tau at S262 (located within the microtubule-binding repeat), disrupting tau–microtubule binding and promoting neurofibrillary tangle formation
- Chronic AMPK hyperactivation suppresses mTORC1-dependent synaptic protein synthesis, contributing to synapse loss
- AMPK-dependent dendritic spine retraction via cofilin activation may underlie synaptic weakening in early AD
Postmortem AD brains show elevated activated AMPK (phospho-Thr172) co-localizing with tangle-bearing neurons in the hippocampus and [entorhinal cortex](/brain-regions/entorhinal-cortex). AMPKα2 is the predominant isoform in these neurons, suggesting PRKAA2 specifically drives the pathological tau phosphorylation.
Parkinson's Disease (PD)
In [PD](/diseases/parkinsons-disease), AMPK plays a largely protective role through its regulation of mitophagy and mitochondrial quality control:
- AMPK phosphorylates [ULK1](/genes/ulk1), initiating [PINK1](/genes/pink1)/[Parkin](/genes/prkn)-dependent mitophagy to clear damaged mitochondria — a process that is defective in familial PD
- AMPK activation by metformin or compound 991 rescues mitochondrial dysfunction in [PINK1](/genes/pink1)-knockout dopaminergic neurons
- AMPK promotes mitochondrial fission through [DRP1](/proteins/drp1-protein) phosphorylation, enabling selective mitophagy of damaged mitochondrial fragments
- Conversely, excessive AMPK activation in energy-depleted dopaminergic neurons may trigger [apoptosis](/entities/apoptosis) through p53 stabilization
In MPTP and rotenone PD models, AMPK is acutely activated as a compensatory response to Complex I inhibition. Short-term AMPK activation is protective, but sustained activation (reflecting chronic energy failure) correlates with dopaminergic neuron loss. AMPKα2-specific knockout in midbrain dopaminergic neurons accelerates MPTP-induced neurodegeneration, confirming a predominantly neuroprotective role.
Huntington's Disease (HD)
[Huntingtin (HTT)](/huntingtin-)))))))))) aggregates in [HD](/diseases/huntingtons) impair mitochondrial function and energy metabolism, leading to chronic AMPK activation in striatal medium spiny neurons. AMPK activation in HD has dual consequences:
- Protective: Enhanced [autophagy](/entities/autophagy) promotes clearance of mutant [huntingtin](/proteins/huntingtin) aggregates
- Detrimental: AMPK hyperactivation phosphorylates huntingtin at S421 (via AMPK-dependent activation of DAPK1), which paradoxically reduces the protective phosphorylation by [AKT1](/genes/akt1) at the same site
Amyotrophic Lateral Sclerosis (ALS)
AMPK is activated in motor neurons of [ALS](/diseases/amyotrophic-lateral-sclerosis) patients and SOD1-G93A mice. AMPKα2 activation in motor neurons enhances [TDP-43](/genes/tardbp) phosphorylation and promotes stress granule formation, potentially contributing to the gain-of-toxic-function mechanism. However, AMPK-driven autophagy is beneficial for clearing [TDP-43](/genes/tardbp) and [FUS](/entities/fus) aggregates. The net effect appears to be disease-stage dependent.
Type 2 Diabetes and Brain Insulin Resistance
PRKAA2 mutations and polymorphisms are associated with type 2 diabetes, metabolic syndrome, and obesity. Brain insulin resistance — a feature of AD sometimes called "type 3 diabetes" — involves impaired insulin-mediated AMPK regulation. Metformin, the most widely prescribed antidiabetic drug, activates AMPK and has shown epidemiological association with reduced dementia risk.
Common Variants
| Variant | Type | Association | Reference |
|---------|------|-------------|-----------|
| rs2796498 | Intronic | Type 2 diabetes susceptibility | [Horikoshi et al., 2006](https://doi.org/10.1007/s00125-006-0319-3) |
| rs2796516 | Intronic | Metabolic syndrome, insulin resistance | [Spencer-Jones et al., 2006](https://doi.org/10.2337/db05-1037) |
| c.1547G>A (R516Q) | Missense | Reduced kinase activity, Wolff-Parkinson-White variant | [Arad et al., 2007](https://doi.org/10.1161/CIRCULATIONAHA.107.706523) |
| rs10789038 | Intronic | Nominal association with hippocampal volume | [Genome-wide studies](https://www.ebi.ac.uk/gwas/) |
Therapeutic Implications
AMPK Activators for Neurodegeneration
- Metformin: FDA-approved biguanide antidiabetic that activates AMPK indirectly (via Complex I inhibition and AMP:ATP elevation). Epidemiologically associated with reduced dementia incidence. The TAME (Targeting Aging with Metformin) trial is ongoing. Brain-penetrant but with limited CNS bioavailability
- AICAR (acadesine): AMP mimetic that directly activates AMPK. Improves memory in AD mouse models but has poor brain penetration
- Compound 991 / PF-06409577: Direct AMPK activators (binding the ADaM site between α and β subunits) with improved potency and selectivity. PF-06409577 is α1-selective; α2-selective activators are under development
- A-769662: Direct AMPK activator; protects against neuronal death in ischemia models
- Resveratrol: Natural polyphenol that activates AMPK indirectly via SIRT1-dependent LKB1 deacetylation. Neuroprotective in multiple models but limited by bioavailability
- Berberine: Natural alkaloid that activates AMPK; protective in AD and PD models
AMPK Inhibitors (Disease-Stage-Specific)
- Compound C (dorsomorphin): Non-selective AMPK inhibitor used as a research tool. May be beneficial in contexts where chronic AMPK hyperactivation drives pathological tau phosphorylation
- SBI-0206965: ULK1 inhibitor that blocks AMPK-induced autophagy; useful for dissecting AMPK-dependent vs. -independent autophagy in disease models
Precision Medicine Considerations
Given AMPK's dual roles (protective autophagy vs. detrimental tau phosphorylation), therapeutic AMPK modulation in neurodegeneration requires:
Disease-stage stratification (early vs. late)
Isoform selectivity (α2-selective activators for neurons vs. α1 for glia)
Pathway-specific modulation (enhancing AMPK→ULK1→autophagy while avoiding AMPK→tau phosphorylation)Expression Profile
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Hypothalamus (arcuate nucleus) | Very High | Neurons (AGRP, POMC) |
| Hippocampus (CA1, CA3, DG) | High | Pyramidal neurons, granule cells |
| Cerebral cortex | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule neurons |
| Substantia nigra | Moderate | Dopaminergic neurons |
| Striatum | Moderate | Medium spiny neurons |
| Spinal cord | Moderate | Motor neurons |
See Also
- [PRKAA1](/genes/prkaa1) — AMPKα1, catalytic subunit isoform predominant in glia
- [STK11](/genes/stk11) — LKB1, primary upstream AMPK kinase
- [MTOR](/genes/mtor) — [mTOR](/mechanisms/mtor-signaling-pathway) kinase, major AMPK target (inhibited)
- [TSC2](/genes/tsc2) — Tuberin, AMPK substrate linking to mTORC1 inhibition
- [ULK1](/genes/ulk1) — ULK1 autophagy-initiating kinase, direct AMPK substrate
- [PPARGC1A](/genes/ppargc1a) — PGC-1α, AMPK-activated mitochondrial biogenesis co-activator
- [LATS1](/genes/lats1) — LATS1 Hippo kinase, AMPK substrate
- [MAPT](/genes/mapt) — Tau, direct AMPK phosphorylation substrate
- [Autophagy](/mechanisms/autophagy) — Cellular degradation pathway regulated by AMPK
- [Energy Metabolism in Neurodegeneration](/energy-metabolism-in-neurodegeneration)
External Links
- [NCBI Gene: PRKAA2](https://www.ncbi.nlm.nih.gov/gene/5563)
- [UniProt: P54646](https://www.uniprot.org/uniprot/P54646)
- [GeneCards: PRKAA2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRKAA2)
- [OMIM: 600497](https://omim.org/entry/600497)
- [Allen Brain Atlas: PRKAA2](https://human.brain-map.org/)
References
[Unknown, Herzig & Shaw, AMPK: guardian of metabolism and mitochondrial homeostasis (2018) (2018)](https://doi.org/10.1038/nrm.2017.95)
[Unknown, Steinberg & Carling, AMP-activated protein kinase: the current landscape for drug development (2019) (2019)](https://doi.org/10.1038/s41573-019-0019-2)
[Salminen et al., AMP-activated protein kinase: a potential player in Alzheimer's disease (2011) (2011)](https://doi.org/10.1111/j.1471-4159.2011.07331.x)
[Vingtdeux et al., AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in AD (2011) (2011)](https://doi.org/10.1007/s00401-010-0759-x)
[Curry et al., Targeting AMPK signaling as a neuroprotective strategy in Parkinson's disease (2018) (2018)](https://doi.org/10.3233/JPD-181296)
[Unknown, Dasgupta & Bhatt, AMPK and neuronal metabolism (2016) (2016)](https://doi.org/10.1016/j.cmet.2016.05.013)
[Thornton et al., Metformin and neurodegeneration: a systematic review (2022) (2022)](https://doi.org/10.1016/j.jalz.2022.02.013)
[Kim et al., AMPK activators: mechanisms of drug action and physiological activities (2016) (2016)](https://doi.org/10.1038/nrd.2015.34)
[Cai et al., Roles of AMP-activated protein kinase in Alzheimer's disease (2012) (2012)](https://doi.org/10.1016/j.neuromolmed.2012.08.006)
[Poels et al., AMPK and exercise: glucose uptake, mitochondrial biogenesis, and neuroplasticity (2020) (2020)](https://doi.org/10.3390/ijms21186344)Pathway Diagram
The following diagram shows the key molecular relationships involving PRKAA2 (AMPKα2) — AMP-Activated Protein Kinase Catalytic Subunit Alpha 2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)